Core Insights - AsymBio, a subsidiary of Asymchem Group, has officially commenced operations at its Fengxian commercial manufacturing site in Shanghai, completing a strategic "Golden Triangle" footprint that enhances its CDMO capabilities [1][9] Group 1: Operational Capabilities - The "Dual Sites + One Center" model allows for connected functions and complementary strengths across the biologics lifecycle, supporting flexible capacity needs from early pilot to large-scale commercial supply [2][3] - The Zhangjiang Science & Technology Center focuses on early R&D and process development for advanced therapies, optimizing technology platforms for various drug development processes [5] - The Jinshan Site provides comprehensive manufacturing services from clinical supply to commercial production, covering both drug substance and drug product capabilities [5] - The Fengxian Site is designed for late-stage development and large-scale commercial supply, utilizing advanced smart manufacturing systems to meet global demand for high-quality biologics [5] Group 2: Manufacturing Capabilities - The network includes single-use bioreactors with capacities of 200 L, 500 L, and 2,000 L for antibody drug substances, and conjugation reactors with capacities ranging from 50 L to 500 L [6] - Multi-specification lyophilization and isolator filling systems support diverse dosage forms, enhancing integrated delivery in biologics [7] Group 3: Integrated Services - AsymBio integrates its Shanghai conjugation manufacturing with the Tianjin payload-linker R&D and manufacturing capabilities, ensuring supply chain stability and improving execution efficiency [8] - The operational footprint now covers the full value chain from early-stage development through commercialization, providing global clients with efficient and customized development and manufacturing solutions [9] Group 4: Company Overview - AsymBio specializes in biopharmaceutical CDMO services, leveraging over 25 years of experience to offer one-stop services from early-stage development to commercial-scale manufacturing [10]

Core Insights - AsymBio has officially commenced commercial production at its Shanghai Fengxian Commercial Manufacturing Base, enhancing its integrated biologics CDMO services and commitment to innovative therapies [1][4] Facility Overview - The Fengxian facility spans 130,000 square meters and serves as a strategic hub within AsymBio's global network, providing flexible and scalable support across all clinical phases [2] - The facility is designed to offer tailored CDMO solutions from early development through to commercial production [2] Advanced Manufacturing Capabilities - The Fengxian base is equipped to manufacture a wide range of next-generation biotherapeutics, including ADCs, dual-payload ADCs, RDCs, APCs, PDCs, AOCs, monoclonal, bispecific, and multispecific antibodies, as well as recombinant proteins [3] Leadership and Strategic Goals - CEO Rui Yang emphasized that the launch of the Fengxian Base is a strategic milestone for global expansion, enhancing production capacity and service capabilities while strengthening supply chain resilience [4] Quality and Sustainability Commitment - The Fengxian facility operates under a quality management system that meets global regulatory standards and employs advanced biomanufacturing technology for cost reduction and flexibility [4] - The site adheres to Asymchem's ESG strategy and EHS management principles [4] Business Focus - AsymBio specializes in biopharmaceutical CDMO services, leveraging advanced technology platforms and extensive project experience to provide one-stop solutions for global clients [5]